The PCCTC at SES AUA 2025: Phase 1 Trial of Mevrometostat (PF-06821497), a Potent and Selective Inhibitor of EZH2, in CRPC

Written By Kristofer Prepelica, PhD

https://www.urotoday.com/conference-highlights/ses-aua-2025/ses-aua-2025-prostate-cancer/158985-ses-aua-2025-phase-1-trial-of-mevrometostat-pf-06821497-a-potent-and-selective-inhibitor-of-ezh2-in-crpc.html

Kristofer Prepelica, PhD
Previous

Dr. Howard I. Scher Honored with Richard D. Williams, MD Prostate Cancer Research Excellence Award
Next

The PCCTC at ASCO GU 2025